MedTrace Logo

A Study To See Why Patients Agree To or Decline To Have Treatment After Surgery

NCT03843593 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 38

Last updated 2023-01-04

No results posted yet for this study

Summary

The purpose of this study is to find out what patients consider when deciding whether or not to receive adjuvant treatment, and how patients feel about their decision after one year.

Conditions

Interventions

BEHAVIORAL

Demographics Questionnaire

A brief questionnaire will collect basic demographic information (i.e., age, gender, racial background, ethnicity, employment status, marital status) at time of enrollment.

BEHAVIORAL

Adjuvant Treatment Beliefs Scale10

This brief PRO measure asks patients to indicate the likelihood, using a 5-point Likert type scale (1 \[definitely not\], 2 \[probably not\], 3 \[maybe\], 4 \[probably\], 5 \[definitely\]) of six positive (e.g., reduced risk of recurrence, greater chance of being cured) and five negative outcomes (e.g., side effects, health status) of adjuvant treatment.

BEHAVIORAL

Functional Assessment of Cancer Therapy - Melanoma (FACT-M)11

FACT-M is a 51-item patient-self report measure for the assessment of quality of life (QOL) in patients with American Joint Committee on Cancer stages I through IV melanoma.

BEHAVIORAL

Functional Assessment of Chronic Illness Therapy - Treatment Satisfaction - General (FACIT-TS-G)13

FACIT-TS-G is a brief, 8-item self-administered measure designed to assess general treatment satisfaction in patients.

BEHAVIORAL

Decisional Regret14

This is a set of 5 questions examining level of regret for treatment decisions (in this case, decision to pursue adjuvant therapy), with answers scored on a 5-point Likert-type scale (i.e., 1 \[Strongly Agree\], 2 \[Agree\], 3 \[Neither Agree Nor Disagree\], 4 \[Disagree\], 5 \[Strongly Disagree\].

BEHAVIORAL

Clinician Preference for Treatment

This is a single item to be completed by Medical Oncologists that will indicate their preference as to whether they prefer that their patient accepts adjuvant therapy.

Sponsors & Collaborators

Principal Investigators

  • Paul Chapman, MD · Memorial Sloan Kettering Cancer Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-14
Primary Completion
2022-12-29
Completion
2022-12-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03843593 on ClinicalTrials.gov